These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35452850)

  • 1. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases.
    Danieli MG; Tonacci A; Paladini A; Longhi E; Moroncini G; Allegra A; Sansone F; Gangemi S
    Autoimmun Rev; 2022 Jun; 21(6):103105. PubMed ID: 35452850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A machine learning analysis to evaluate the outcome measures in inflammatory myopathies.
    Danieli MG; Paladini A; Longhi E; Tonacci A; Gangemi S
    Autoimmun Rev; 2023 Jul; 22(7):103353. PubMed ID: 37142194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
    Gandiga PC; Ghetie D; Anderson E; Aggrawal R
    Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world single centre experience.
    Ma Z; Johnson D; Gniadecki R; Ritchie B; Keeling S; Cohen Tervaert JW; Osman M
    Rheumatology (Oxford); 2023 Oct; ():. PubMed ID: 37796840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
    Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
    Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
    Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
    Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
    Anh-Tu Hoa S; Hudson M
    Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis.
    Goswami RP; Haldar SN; Chatterjee M; Vij P; van der Kooi AJ; Lim J; Raaphorst J; Bhadu D; Gelardi C; Danieli MG; Kumar U
    Autoimmun Rev; 2022 Feb; 21(2):102997. PubMed ID: 34800685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy.
    Zuppa A; De Michelis C; Meo G; Prada V; Gemelli C; Infantino M; Manfredi M; Pesce G; Tagliafico AS; Benedetti L; Fiorillo C; Schenone A; Quartuccio L; Grandis M
    Neuromuscul Disord; 2021 Feb; 31(2):134-138. PubMed ID: 33461845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial.
    Kamperman RG; Bogaards JA; Evers SW; Walter HAW; de Visser M; de Borgie C; Colen-de Koning JCA; Verhamme C; Maas M; Eftimov F; van Schaik IN; van der Kooi AJ; Raaphorst J
    BMJ Open; 2023 Jul; 13(7):e067435. PubMed ID: 37429682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin therapy in statin-induced necrotizing autoimmune myopathy.
    Mak VP; Gravely K; Lim SY
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):58-61. PubMed ID: 32967573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study.
    Barsotti S; Cavazzana I; Zanframundo G; Neri R; Taraborelli M; Cioffi E; Cardelli C; Tripoli A; Codullo V; Tincani A; Cavagna L; Franceschini F; Mosca M
    Autoimmun Rev; 2021 Mar; 20(3):102757. PubMed ID: 33476815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
    Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
    Quick A; Tandan R
    Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.